3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Expanded_access
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
16
Lung Neoplasms
8
Lymphoma, Large-Cell, Anaplastic
4
Carcinoma
3
Brain Neoplasms
2
ALK-positive Advanced NSCLC
2
Neuroma, Acoustic
1
Neurofibromatosis 2
1
Neoplasms
1
Neoplasm Metastasis
1
NSCLC
1
Meningioma
1
Granuloma, Plasma Cell
1
Gastrointestinal Neoplasms
1
Ependymoma
1
Disease Progression
1
Carcinoma, Squamous Cell
1
Carcinoma, Pancreatic Ductal
1
Carcinoma, Large Cell
1
Breast Neoplasms
1
Adenocarcinoma
1
ALK+ Advanced NSCLC
1
Interventions
Oxaliplatin
46
Gemcitabine
45
Fluorouracil
40
Capecitabine
31
pembrolizumab
29
Leucovorin
29
Docetaxel
27
Cisplatin
25
Paclitaxel
23
Irinotecan
18
Carboplatin
18
Bevacizumab
18
130-nm albumin-bound paclitaxel
17
Pemetrexed
15
Albumin-Bound Paclitaxel
15
Radiotherapy
14
Nivolumab
12
Ramucirumab
11
Cyclophosphamide
11
Trastuzumab
8
Erlotinib Hydrochloride
8
Taxes
7
Radiosurgery
7
Drug Therapy
7
cemiplimab
6
zolbetuximab
5
trastuzumab deruxtecan
5
regorafenib
5
durvalumab
5
Sorafenib
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Adenocarcinoma
×
brigatinib
×
Clear all
NCT02737501
2021-08-20
ALTA-1L
Takeda
Phase 3
Completed
275 enrolled
23 charts
1 FDA